Ryan Sweeney

UPMC Heme/Onc Fellow | AHN IM '24 | Loyola Stritch '21 | Notre Dame '17 | Views are my own/not medical advice

[Anwaar Saeed @AnwaarSaeed3]

🌤️ The pancreatic cancer story is changing. RAS inhibitors are opening one front. Precision IO may be opening another. @ASCO 2026 we presented promising early 1L mPDAC data with CLDN18.2/CD47 bispecific spevatamig (PT886): ORR 52%, DCR 90.5%, mOS 14.7 months. ✨For the 1st time in decades, it feels like the code of this lethal disease is finally breaking✨.
@UPMCHillmanCC @OncoAlert @OncUpdates @OncBrothers

[Ryan Sweeney @RyanSweeneyMD]

Honored to serve a program that has done so much for me and to do so alongside the best co-chief 🫡 Looking forward to an exciting academic year!

[UPMC Heme-Onc Fellowship Program @UPMCHeme_Onc]

🎉 We’re thrilled to announce Dr. Randolph Lyde MD, PhD and Dr. Ryan Sweeney MD as our new Chief Fellows for coming academic year! Your leadership, dedication, and commitment to our program are truly inspiring. Here’s to a bright and exciting year ahead!✨#Congrats #ChiefFellows

[Ryan Sweeney @RyanSweeneyMD]

Thank you to @MPishvaian and @TumorBoardTues for the opportunity and of course to my incredible mentor @AnwaarSaeed3 for the privilege to co-present this exciting data! 🙏📈

[Mike Pishvaian @MPishvaian]

@RyanSweeneyMD @TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO @TheLancet #tumorboardtuesday

🧐I don't know about you all - but I now feel fully prepared and confident in offering a patient zanza + atezo (assuming the combination gets approved)

🙏Thank you @AnwaarSaeed3 and @RyanSweeneyMD. That was a highly instructive session

[Ryan Sweeney @RyanSweeneyMD]

@AnwaarSaeed3 @MPishvaian @TumorBoardTues @IntegrityCE @myESMO @TheLancet Excellent question, I think STELLAR-303 opens up many avenues for further research now that there is data for a role of IO in this space!

[Ryan Sweeney @RyanSweeneyMD]

@TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO @TheLancet #PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 https://t.co/cwslkJPpvF
🧐 In the phase 3 STELLAR-303 study of zanzalintinib ➕ atezolizumab versus regorafenib for previously treated mCRC, the combination demonstrated survival benefits in tumors that were:

[Ryan Sweeney @RyanSweeneyMD]

@TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO @TheLancet #PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 https://t.co/HrNzulQcVl
👉🏽ALL CME🔗 https://t.co/cwslkJPpvF

🤔 Which is NOT true about dMMR/MSI-H CRCs compared with those that are that are pMMR/MSS❓

[Ryan Sweeney @RyanSweeneyMD]

@TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO @TheLancet 🔗⬇️
https://t.co/TybjUB6Gy0